Europe Clinical Trials Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The clinical trials market in Europe is projected to grow significantly, reaching approximately USD 20,056.53 million by 2031, up from USD 12,286.73 million in 2023, reflecting a compound annual growth rate (CAGR) of 6.3% during this period.

Executive Summary and Market Analysis

The European clinical trials market is divided into several regions, including the UK, France, Germany, Italy, Spain, Poland, Switzerland, Sweden, Denmark, Belgium, the Netherlands, and other parts of Europe. The anticipated growth in this market is driven by an increase in clinical trial activities aimed at developing new drugs and launching innovative products. The market benefits from strong regulatory frameworks, a robust healthcare infrastructure, and a heightened focus on addressing rare and chronic diseases. Regulatory bodies and governments emphasize transparency and patient safety, while collaborations with contract research organizations (CROs) enhance operational efficiency. However, challenges such as lengthy approval processes and high costs persist.

Market Segmentation Analysis

The Europe clinical trials market can be analyzed through various segments, including study design, indications, and phase type.

1. Study Design: The market is categorized into interventional trials and expanded access trials, with interventional trials holding a larger market share in 2023.

2. Indications: The market is segmented into various therapeutic areas, including autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular diseases, and others. Oncology represented the largest share in 2023.

3. Phase Type: The market is divided into phase I, phase II, and phase III trials, with phase II trials dominating the market share in 2023.

Market Outlook

Decentralized clinical trials (DCTs) are gaining traction as they allow participants to engage in trials without frequent visits to hospital sites. These trials utilize digital technologies for remote data collection, monitoring, and communication between researchers and participants. A hybrid approach, which combines home-based and on-site activities, is also becoming popular, enhancing patient experience and accommodating complex protocols. Initially, the adoption of DCTs faced hurdles such as concerns over patient privacy, data security, regulatory issues, and intricate protocols. However, the COVID-19 pandemic accelerated the shift towards decentralized and hybrid methods, as traditional in-person trials became impractical. Data from McKinsey indicates that around 70% of potential clinical trial participants do not visit trial sites, highlighting the need for decentralization to access a broader and more diverse patient population.

Hybrid trials offer flexibility by integrating DCT elements into study designs, attracting more sponsors and reshaping the clinical trial landscape. The FDA is expected to introduce protocols supporting DCT methods in 2023, further enhancing the credibility of clinical research. The growing emphasis on decentralized and hybrid trials is anticipated to create lucrative opportunities for the clinical trials market in the coming years.

Country Insights

The European clinical trials market includes key countries such as the UK, Germany, France, Spain, Italy, Poland, Switzerland, Sweden, Denmark, Belgium, the Netherlands, and others. Germany is the leading country in this market as of 2023, accounting for approximately 3.9% of global clinical trials conducted in 2021. The country boasts a large patient population and a strong demand for high-quality healthcare. To promote academic clinical research, Germany has established coordinating centers for clinical trials under a funding initiative from the Federal Ministry of Education and Research. Clinical trials in Germany are regulated by the Federal Institute for Drugs and Medical Devices or the Paul-Ehrlich Institute, ensuring standardized, reliable, and transparent approval processes with relatively short timelines. Major CROs in Germany, such as Sofpromed and CONET GmbH, provide comprehensive clinical trial services across various phases and types of studies.

Company Profiles

Key players in the clinical trials market include QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx Research Private Limited, Caidya, Oracle Corp, Medpace Holdings Inc, and SIRO Clinpharm Pvt Ltd. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to clients.

Product Code: BMIRE00028989

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Clinical Trials Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials
- 4.1.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities
4.2 Market Restraints
- 4.2.1 Expensive and Time-Consuming Process
4.3 Market Opportunities
- 4.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
4.4 Future Trends
- 4.4.1 AI-Driven Clinical Trials

5. Clinical Trials Market - Europe Analysis

5.1 Europe Clinical Trials Market Revenue (US$ Million), 2021-2031
5.2 Europe Clinical Trials Market Forecast Analysis

6. Europe Clinical Trials Market Analysis - by Study Design

6.1 Interventional Trials
- 6.1.1 Overview
- 6.1.2 Interventional Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Expanded Access Trials
- 6.2.1 Overview
- 6.2.2 Expanded Access Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Clinical Trials Market Analysis - by Indications

7.1 Autoimmune/Inflammation
- 7.1.1 Overview
- 7.1.2 Autoimmune/Inflammation: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Pain Management
- 7.2.1 Overview
- 7.2.2 Pain Management: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Neurological Disorders
- 7.4.1 Overview
- 7.4.2 Neurological Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Diabetes
- 7.5.1 Overview
- 7.5.2 Diabetes: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Obesity
- 7.6.1 Overview
- 7.6.2 Obesity: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Metabolic Disorders
- 7.7.1 Overview
- 7.7.2 Metabolic Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Cardiovascular
- 7.8.1 Overview
- 7.8.2 Cardiovascular: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.9 Others
- 7.9.1 Overview
- 7.9.2 Others: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Clinical Trials Market Analysis - by Phase Type

8.1 Phase I
- 8.1.1 Overview
- 8.1.2 Phase I: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Phase II
- 8.2.1 Overview
- 8.2.2 Phase II: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Phase III
- 8.3.1 Overview
- 8.3.2 Phase III: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Clinical Trials Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Clinical Trials Market Overview
- 9.1.2 Europe Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Europe Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.2.1 United Kingdom: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.2.2 United Kingdom: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.2.3 United Kingdom: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.3 Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.3.1 Germany: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.3.2 Germany: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.3.3 Germany: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.4 France: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.4.1 France: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.4.2 France: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.4.3 France: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.5 Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.5.1 Spain: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.5.2 Spain: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.5.3 Spain: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.6 Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.6.1 Italy: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.6.2 Italy: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.6.3 Italy: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.7 Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.7.1 Poland: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.7.2 Poland: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.7.3 Poland: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.8 Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.8.1 Switzerland: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.8.2 Switzerland: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.8.3 Switzerland: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.9 Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.9.1 Sweden: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.9.2 Sweden: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.9.3 Sweden: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.10 Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.10.1 Denmark: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.10.2 Denmark: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.10.3 Denmark: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.11 Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.11.1 Belgium: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.11.2 Belgium: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.11.3 Belgium: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.12 Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.12.1 Netherlands: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.12.2 Netherlands: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.12.3 Netherlands: Europe Clinical Trials Market Share - by Phase Type
  - 9.1.2.13 Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.13.1 Rest of Europe: Europe Clinical Trials Market Share - by Study Design
    - 9.1.2.13.2 Rest of Europe: Europe Clinical Trials Market Share - by Indications
    - 9.1.2.13.3 Rest of Europe: Europe Clinical Trials Market Share - by Phase Type

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players
10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Clinical Trials Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 QVIA Holdings Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Parexel International Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 IXICO Plc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Charles River Laboratories International Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 ICON Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 WuXi AppTec Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 SGS SA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Syneos Health Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SIRO Clinpharm Pvt Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Thermo Fisher Scientific Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Laboratory Corp of America Holdings
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
12.12 CliniRx Research Private Limited
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 Financial Overview
- 12.12.5 SWOT Analysis
- 12.12.6 Key Developments
12.13 Caidya
- 12.13.1 Key Facts
- 12.13.2 Business Description
- 12.13.3 Products and Services
- 12.13.4 Financial Overview
- 12.13.5 SWOT Analysis
- 12.13.6 Key Developments
12.14 Oracle Corp
- 12.14.1 Key Facts
- 12.14.2 Business Description
- 12.14.3 Products and Services
- 12.14.4 Financial Overview
- 12.14.5 SWOT Analysis
- 12.14.6 Key Developments
12.15 Medpace Holdings Inc
- 12.15.1 Key Facts
- 12.15.2 Business Description
- 12.15.3 Products and Services
- 12.15.4 Financial Overview
- 12.15.5 SWOT Analysis
- 12.15.6 Key Developments

13. Appendix

13.1 About Us
13.2 List of Abbreviations